Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Teva-discovered TEV ‘408, a novel anti-IL-15 monoclonal antibody, demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage vs placebo following a single subcutaneous dose. TEV ‘408 was well-tolerated with no safety signals observed to date. Together with the vitiligo program, the celiac disease topline results further support TEV ‘408 as a potential pipeline-in-a-product […]